Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
Methods for identifying broadly neutralizing antibodies utilizing recombinant HIV-1 envelope glycoproteins comprising stabilizing mutations
US9562078B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9562078-B2 |
| Application number | US-201313928561-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 27, 2013 |
| Priority date | Jun 27, 2012 |
| Publication date | Feb 7, 2017 |
| Grant date | Feb 7, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for screening broad neutralizing antibodies comprising contacting a non-naturally occurring soluble HIV-1 envelope glycoprotein isolated from a 16055 virus comprising a L111A, T332N or L111A/T332N mutation(s), wherein said numbering scheme is based upon alignment with HXB2 reference strain of HIV-1 envelope glycoprotein, with an animal or human sera, isolating the glycoprotein complexed to the broad neutralizing antibodies, and testing the activity of the broad neutralizing antibodies in a neutralization assay or a pseudoneutralization assay to determine if the sera is neutralizing, thereby screening for a broad neutralizing antibody. 2. The glycoprotein of claim 1 , wherein the mutation is L111A. 3. The glycoprotein of claim 1 , wherein the mutation is T332N. 4. The glycoprotein of claim 1 , wherein the mutation is L111A/T332N. 5. A method for screening broad neutralizing antibodies comprising contacting a non-naturally occurring soluble HIV-1 envelope glycoprotein isolated from 6535 virus, a 13095 virus, a 25710 virus, a 25925 virus, a CAAN virus or a Zm109F virus comprising a L111A, T332N or L111A/T332N mutation(s), wherein said numbering scheme is based upon alignment with HXB2 reference strain of HIV-1 envelope glycoprotein, with an animal or human sera, isolating the glycoprotein complexed to the broad neutralizing antibodies, and testing the activity of the broad neutralizing antibodies in a neutralization assay or a pseudoneutralization assay to determine if the sera is neutralizing, thereby screening for a broad neutralizing antibody. 6. The glycoprotein of claim 1 , wherein the mutation is L111A. 7. The glycoprotein of claim 1 , wherein the mutation is T332N. 8. The glycoprotein of claim 1 , wherein the mutation is L111A/T332N.
Assignees
Inventors
Classifications
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
- C07K14/005Primary
from viruses · CPC title
Retroviridae, e.g. equine infectious anemia virus · CPC title
Proteins; Peptides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9562078B2 cover?
- The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).